r-hLIF for Improving Embryo Implantation in IVF

NCT ID: NCT00504530

Last Updated: 2017-01-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-09-30
• Study Completion Date: 2002-04-30

Brief Summary

This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.

Conditions

Infertility Implantation Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Pre-menopausal woman aged 21 to 36 years, inclusive, at time of consent

2. Infertile woman who justified IVF-ET or ICSI-ET treatment and who wished to conceive

3. A history of at least three ART cycles resulting in a transfer of at least two apparently healthy embryos and no evidence of implantation menstruation and/or beta hCG < 10 IU/L at the end of the cycle)

4. Had regular ovulatory spontaneous menstrual cycles lasting 25 to 35 days

5. Had FSH assessment (early follicular day 2 to 5) within the past six months < 12 IU/L

6. No other diagnosed cause of previous ART failure other than recurrent implantation failure

7. A body mass index (BMI) of ³ 20 and £ 30 kg/m2, calculated according to the following formula: BMI (kg/m2) = Body Weight (kg) / Height * Height (m2)

8. The presence of both ovaries

9. A uterine cavity without abnormalities which, in the investigator's opinion, could impair embryo implantation or pregnancy outcome, as assessed by ultrasound (US) examination performed within six months prior to beginning GnRH-agonist therapy

10. Normal cervical cytology within three years prior to beginning GnRH- agonist therapy.

11. At least one wash-out cycle (defined as ³ 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment, prior to beginning GnRH-agonist therapy

12. Male partner semen analysis within the six months prior to starting GnRH agonist therapy

13. Had a negative pregnancy test (urinary) within seven days of commencing GnRH-agonist therapy.

14. Willingness and ability to comply with the protocol for the duration of the study

15. Written informed consent given prior to any study related procedure not part of the patient's normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion Criteria

1. Known to be positive for Human Immunodeficiency Virus

2. Known to be positive for Hepatitis B or C Virus

3. Known allergy to E. coli derived pharmaceutical product

4. Any clinically significant systemic disease (e.g. insulin-dependant diabetes mellitus, epilepsy, severe migraine, intermittent porphyria, hepatic, renal or cardiovascular disease, severe corticosteroid-dependent asthma) or any significant allergic disease (excluding rhinitis, hay fever or sinusitis of ENT origin)

5. Presence of an uncontrolled clinically significant medical condition (including infection) as determined by the investigator

6. Persistent tachycardia defined as heart rate > 90 bpm confirmed by ECG

7. Any medical condition, which in the judgement of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the patient in question was to be discussed with Serono's Study Director

8. More than one previous failed ART cycle, where "failed" is defined as cancellation of administration of hCG due to a poor response to gonadotrophin stimulation (defined as retrieval of three oocytes or less)

9. Any history of difficulties in ET procedure (i.e. requiring general anaesthetic e.g. due to position of cervix)

10. Hyperprolactinaemia, defined as prolactin levels of ³ 1000 mIU/L and/or the patient remained anovulatory despite appropriate dopamine agonist treatment

11. Abnormal undiagnosed gynaecological bleeding

12. Any contraindication to being pregnant and/or carrying pregnancy to term

13. Presence of any medical condition for which the use of gonadotrophin preparations or progesterone was contra-indicated

14. Known allergy or hypersensitivity to gonadotrophin preparations

15. Known intolerance or allergy to paracetamol (acetaminophen)

16. Active substance abuse

17. Previous entry into this study or simultaneous participation in another clinical drug trial

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 36 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Merck KGaA, Darmstadt, Germany

INDUSTRY

Sponsor Role: lead

Principal Investigators

Peter Brinsden, M.D.

Role: PRINCIPAL_INVESTIGATOR

Bourn Hall Clinic, Bourn Hall, High Street, Bourn, Cambridge CB3 7TR

References

Paterson JM, Smith SM, Simpson J, Grace OC, Sosunov AA, Bell JE, Antoni FA. Characterisation of human adenylyl cyclase IX reveals inhibition by Ca(2+)/Calcineurin and differential mRNA plyadenylation. J Neurochem. 2000 Oct;75(4):1358-67. doi: 10.1046/j.1471-4159.2000.0751358.x.

Reference Type: RESULT

PMID: 10987815 (View on PubMed)

Other Identifiers

23079

Identifier Type: -

Identifier Source: org_study_id